<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract" xml:lang="en"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">World Allergy Organ J</journal-id><journal-id journal-id-type="iso-abbrev">World Allergy Organ J</journal-id><journal-title-group><journal-title>The World Allergy Organization Journal</journal-title></journal-title-group><issn pub-type="epub">1939-4551</issn><publisher><publisher-name>World Allergy Organization</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">4082099</article-id><article-id pub-id-type="publisher-id">1939-4551-7-S1-P16</article-id><article-id pub-id-type="doi">10.1186/1939-4551-7-S1-P16</article-id><article-categories><subj-group subj-group-type="heading"><subject>Poster Presentation</subject></subj-group></article-categories><title-group><article-title>Poster 1026: Randomized clinical trial to evaluate oral dializable leukocyte extracts as immunemodulator treatment in atopic dermatitis</article-title></title-group><contrib-group><contrib contrib-type="author" id="A1"><name><surname>Garc&#x000ed;a</surname><given-names>Alejandro Estrada</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" corresp="yes" id="A2"><name><surname>Carre&#x000f3;n</surname><given-names>Jorge Galicia</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A3"><name><surname>Ram&#x000ed;rez</surname><given-names>Erika</given-names></name><xref ref-type="aff" rid="I3">3</xref></contrib><contrib contrib-type="author" id="A4"><name><surname>Toledo</surname><given-names>Mirna</given-names></name><xref ref-type="aff" rid="I3">3</xref></contrib><contrib contrib-type="author" id="A5"><name><surname>Parra</surname><given-names>Sergio Estrada</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A6"><name><surname>Tapia</surname><given-names>Mayra P&#x000e9;rez</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A7"><name><surname>Jim&#x000e9;nez Mart&#x000ed;nez</surname><given-names>Mar&#x000ed;a Del Carmen</given-names></name><xref ref-type="aff" rid="I4">4</xref></contrib></contrib-group><aff id="I1"><label>1</label>National Polytechnic Institute, Mexico., Department of Immunology, National School of Biological Sciences, Mexico City, Mexico</aff><aff id="I2"><label>2</label>Faculty of Medicine, National Autonomous University of Mexico, Department of Immunology, Research Unit, &#x0201c;Conde de Valenciana&#x0201d; Foundation, Mexico, Mexico City, Mexico</aff><aff id="I3"><label>3</label>National Autonomous University of Mexico, Paediatrics Dermatology Department, Hospital Infantil de M&#x000e9;xico Federico G&#x000f3;mez, Mexico, Mexico City, Mexico</aff><aff id="I4"><label>4</label>Universidad Nacional Aut&#x000f3;noma de M&#x000e9;xico, Faculty of Medicine, Mexico City, Mexico</aff><pub-date pub-type="collection"><year>2014</year></pub-date><pub-date pub-type="epub"><day>3</day><month>2</month><year>2014</year></pub-date><volume>7</volume><issue>Suppl 1</issue><supplement><named-content content-type="supplement-title">2013 WAO Symposium on Immunotherapy and Biologics</named-content><named-content content-type="supplement-sponsor">Publication of this supplement was supported by the World Allergy Organization.</named-content></supplement><fpage>P16</fpage><lpage>P16</lpage><permissions><copyright-statement>Copyright &#x000a9; 2014 Garc&#x000ed;a et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2014</copyright-year><copyright-holder>Garc&#x000ed;a et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><self-uri xlink:href="http://www.waojournal.org/content/7/S1/P16"/><conference><conf-date>13-14 December 2013</conf-date><conf-name>2013 WAO Symposium on Immunotherapy and Biologics</conf-name><conf-loc>Chicago, IL, USA</conf-loc></conference></article-meta></front><body><sec><title>Background</title><p>To investigate efficacy and safety of Dialyzed Leukocyte Extracts (DLE) as adjuvant therapy for moderate atopic dermatitis (AD).</p></sec><sec><title>Design</title><p>Double blind, placebo-controlled, randomized, clinical single-centre trial.</p></sec><sec sec-type="methods"><title>Methods</title><p>Fifty-eight paediatric-patients with moderate AD were enrolled and randomized in two groups: 1) Conventional treatment (CT) + DLE: Cetirizine (0.25mg/kg), once daily/4 weeks, Chlorpheniramine (0.35 mg/Kg), daily divided in 3 doses/4 weeks; and topical Methylprednisolone 0.1%, twice daily/10 days, then once daily/10 days, and ending every 48h/10 days; plus oral DLE (2mg/5mL), daily/5 days, then every 72h to complete one month. 2) CT + placebo, same dosage and administration. Main outcome measures: Severity of skin lesions evaluated with SCORAD-Index, and immunophenotypical changes at day 14, and at end of treatment.</p></sec><sec sec-type="results"><title>Results</title><p>A significant clinical improvement was observed since day 14 with both, CT and CT + DLE therapy, no significant differences in the main clinical outcome measures were found among groups; however a diminished frequency of CD8+ CD103+ cells, and increased frequency of CLA + cells, was observed in CT + placebo-group.</p></sec><sec sec-type="conclusions"><title>Conclusions</title><p>Adjuvant therapy with DLE was safe and well-tolerated. Despite both groups of patients significant improved after treatment, individuals treated with DLE preserved cell subsets related to skin immunological regulation, and avoided systemic expansion of cells related to skin inflammation.</p></sec></body></article>